MetaVia Inc.

MTVA

$1.88

+$0.77 (69.37%)

Closed

Late-breaking ADA 2026 abstract acceptances for DA-1726 spark MetaVia's premarket surge.

Loading chart...

IndexN/A

Market Cap0.00B

Enterprise Value0.00B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-0.44

P/SN/A

P/B2.79

P/C-0.95

EV/EBITDA-0.35

EV/SalesN/A

EPS (ttm)-4.25

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume82.74M

Shs Outstand0.00B

Change69.37%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

May 1808:31AMMetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions(prnewswire.com)

May 1404:05PMMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update(prnewswire.com)

May 1108:31AMMetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026(prnewswire.com)

Apr 1008:30AMMetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

Insider Trading

No insider trades found for MTVA.

MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

CEO: Hyung Heon KimEmployees: 9www.metaviatx.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$24.00K	$7.00K	$28.00K	$72.00K	$67.00K	N/A	N/A	N/A
Gross Profit	$-24.00K	$-7.00K	$-28.00K	$-72.00K	$-67.00K	N/A	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$28.79M	$15.88M	$19.60M	$15.23M	$29.65M	$20.18M	$15.49M	$33.12M
Operating Income	$-28.81M	$-15.89M	$-19.63M	$-15.30M	$-29.72M	$-20.18M	$-15.49M	$-33.12M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-27.59M	$-12.47M	$-13.97M	$-15.28M	$-29.68M	$-21.31M	$-15.53M	$-33.41M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-39.16	$-27.06	$-477.84	$-1742.40	$-4831.20	$-10771.20	$-112860.00	$-213180.00
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MetaVia Inc.

Insider Trading

Discover more